COVID-19：东京大学，甲磺酸萘法莫他（Fusan）出现：预防病毒入侵，临床试验
COVID-19：东京大学
甲磺酸萘法莫他（商品名Fusan）被认为是阻止病毒进入过程的药物。
甲磺酸萘法莫他可预防SARS-CoV-2感染/病毒外膜与受感染细胞的细胞膜的初始融合。
德国：研究小组（1）
3月初，一个德国小组宣布了甲磺酸卡莫他酯（商品名Foypan）对SARS-CoV-2的功效（参考资料1）。
Nafamostat：给药结果
Nafamostat阻滞病毒入侵过程的浓度低于camostat浓度的十分之一。
日本正在开发nafamostat和camostat来治疗急性胰腺炎。
在日本已开处方多年的药物。
为了安全起见，已经积累了足够的临床数据，可以迅速进行临床试验。
东京大学医学科学研究所
https://www.ims.u-tokyo.ac.jp/imsut/jp/about/press/page_00060.html
Identification of an existing Japanese pancreatitis drug, Nafamostat, which is expected to prevent the transmission of new coronavirus infection (COVID-19) March 23, 2020
Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19). The University of Tokyo announced these new findings on March 18, 2020.
According to the new research, Nafamostat can prevent the fusion of the envelope of the virus with host cell surface membranes, the first step in infection with the causative virus SARS-CoV-2. Nafamostat can inhibit the membrane fusion at a concentration less than one-tenth that of Camostat mesylate (brand name: Foypan), which was recently identified by a German group as an inhibitor of SARS-CoV-2 infection (Reference 1).
Both Nafamostat and Camostat were developed in Japan as treatments for pancreatitis and some other diseases. These drugs have been prescribed in Japan for many years and have adequate clinical data with regard to safety.
The University of Tokyo plans to launch clinical trials in April 2020 in order to evaluate the effectiveness of these two drugs for treating COVID-19.
THE INSTITUTE OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO
https://www.ims.u-tokyo.ac.jp/imsut/en/about/press/page_00002.html